Atrys Health SA
MAD:ATRY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.79
4.21
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ATRY stock under the Base Case scenario is 5.33 EUR. Compared to the current market price of 3.27 EUR, Atrys Health SA is Undervalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Atrys Health SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ATRY cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Atrys Health SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Atrys Health SA
Balance Sheet Decomposition
Atrys Health SA
Current Assets | 93.2m |
Cash & Short-Term Investments | 23m |
Receivables | 65.1m |
Other Current Assets | 5.1m |
Non-Current Assets | 509.9m |
Long-Term Investments | 6.2m |
PP&E | 59.6m |
Intangibles | 434.6m |
Other Non-Current Assets | 9.5m |
Current Liabilities | 95.2m |
Accounts Payable | 19.9m |
Accrued Liabilities | 321k |
Other Current Liabilities | 75m |
Non-Current Liabilities | 236.7m |
Long-Term Debt | 197.5m |
Other Non-Current Liabilities | 39.2m |
Earnings Waterfall
Atrys Health SA
Revenue
|
190.8m
EUR
|
Cost of Revenue
|
-63.1m
EUR
|
Gross Profit
|
127.6m
EUR
|
Operating Expenses
|
-126m
EUR
|
Operating Income
|
1.7m
EUR
|
Other Expenses
|
-40.7m
EUR
|
Net Income
|
-39.1m
EUR
|
Free Cash Flow Analysis
Atrys Health SA
EUR | |
Free Cash Flow | EUR |
ATRY Profitability Score
Profitability Due Diligence
Atrys Health SA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Atrys Health SA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ATRY Solvency Score
Solvency Due Diligence
Atrys Health SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
Atrys Health SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATRY Price Targets Summary
Atrys Health SA
According to Wall Street analysts, the average 1-year price target for ATRY is 6.16 EUR with a low forecast of 5.05 EUR and a high forecast of 6.83 EUR.
Dividends
Current shareholder yield for ATRY is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ATRY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Atrys Health SA is a biomedical company, which engages in the research and development of diagnostic services. The company is headquartered in Madrid, Madrid and currently employs 2,397 full-time employees. The company went IPO on 2016-07-22. The company operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. The company has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The firm has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Contact
IPO
Employees
Officers
The intrinsic value of one ATRY stock under the Base Case scenario is 5.33 EUR.
Compared to the current market price of 3.27 EUR, Atrys Health SA is Undervalued by 39%.